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 Appendix 1 Model parameters [posted as supplied by author] 
Parameter Base case Reference/source 
Epidemiological parameters   
Carriage prevalence Age variable All serogroup carriage 
prevalence estimates 
(fixed effect estimates) 
from11 
Average duration of carriage (months) 6.0 Assumed 
Disease incidence (per 100,000) 2.6 (age 
variable) 
Hospital Episode Statistics 
2005/06-2011/12* 
Case fatality rate (percentage) 3.8 (age 
variable) 
Hospital Episode Statistics 
2005/06-2011/12 
Years of life lost Age variable Julie Mills, Office for 
National Statistics, 
personal communication, 
40
 
Natural mortality rates (modified to remove 
deaths due to meningococcal disease) 
Age variable Julie Mills, Office for 
National Statistics, 
personal communication, 
40-48
 
Population - initial size of single birth cohort 679102 49 
Acute treatment parameters   
Hospitalisation rate (%) 100 Assumed† 
Proportion requiring ambulance transfer 0.48 Unpublished data from 
Meningitis Research 
Foundation members 
survey, Laura Clark, 
University of Bristol, 
personal communication 
Proportion who require High Dependency 
Unit care 
0.10 (age 
variable) 
Hospital Episode Statistics 
1998/99-2005/06‡ 
Proportion who require Intensive Therapy 
Unit care 
0.14 (age 
variable) 
Hospital Episode Statistics 
1998/99-2005/06 
Length of stay in the High Dependency Unit 
(days) 
2.7 (age 
variable) 
Hospital Episode Statistics 
1998/99-2005/06 
Length of stay in the Intensive Therapy Unit 
(days) 
4.9 (age 
variable) 
Hospital Episode Statistics 
1998/99-2005/06 
Long-term effects of meningococcal 
disease 
  
Percentage of survivors with minor sequelae 13.8 John Edmunds (London 
School of Hygiene and 
Tropical Medicine) 
personal communication 
Percentage of survivors with major sequelae 6.8 John Edmunds (London 
School of Hygiene and 
Tropical Medicine) 
 Parameter Base case Reference/source 
personal communication 
Quality of life utilities   
Quality of life utility loss for survivors 
without sequelae – short term loss due to 
acute disease (loss over first year) 
0.201 Iain Kennedy (Public 
Health England, 
Colindale) personal 
communication 
Quality of life utility loss for survivors with 
sequelae – short term loss due to acute 
disease over and above the long term loss 
(loss over first year) 
0.139 Iain Kennedy (Public 
Health England, 
Colindale) personal 
communication 
Quality of life utility loss for survivors with 
sequelae – in the long term (loss each year in 
the first and subsequent years) including 
quality of life adjustment factor 
0.222 Disutility from John 
Edmunds (London School 
of Hygiene and Tropical 
Medicine) personal 
communication, with 
quality of life adjustment 
factor of 3 applied 
Quality of life losses in family and 
network members 
  
Quality of life adjustment factor applied to 
short term and long term losses in the 
patient, to allow for family and network 
quality of life loss 
1.48 Al-Janabi (University of 
Birmingham) personal 
communication 
Quality of life adjustment factor applied to 
quality adjusted life years lost through death 
of the person with meningococcal disease, to 
allow for family and network quality of life 
loss 
1.09 Al-Janabi (University of 
Birmingham) personal 
communication 
Litigation   
Percentage of cases arising in a claim, child 1.77 Communication with 
Department of Health 
(Health Protection 
Analytical Team) 
Percentage of cases arising in a claim, adult 3.97 Communication with 
Department of Health 
(Health Protection 
Analytical Team) 
Vaccination parameters   
Vaccination uptake - routine immunisation 
infants (%) 
94.0 50 
Vaccination uptake - routine immunisation 
adolescents (%) 
90.0 51 
Vaccination coverage - 1-17 years catch-up 
(%) 
Age variable 52 
Vaccine wastage (proportion) 0 Assumed 
 Parameter Base case Reference/source 
Strain coverage (%) 88.0 18 
Vaccine efficacy against carriage (%) 30.0 9 
Vaccine efficacy against disease (%) 95.0 19 20 
Duration of protection: 2,3,4 [+12] infant 
course, months 
18 [36] Assumed, based on 34 53 54 
55
 
Duration of protection: 2,4 [+12] infant 
course, months 
18 [36] Assumed, based on 34 53 54 
55
 
Duration of protection: catch-up in 1-4 
years, months 
60 Assumed, based on 34 53 
Duration of protection: catch-up in 5-17 
years, months 
120 Assumed, based on 34 53 
Number of vaccine doses resulting in 1 mild 
reaction (non-fever) 
2199 Assumed, based on 56 
Number of vaccine doses resulting in 1 mild 
reaction (fever), 0-4 years 
45 Assumed, based on 19 20 
Number of vaccine doses resulting in 1 mild 
reaction (fever), 5+ years 
370 Assumed, based on 19 20 
Number of vaccine doses resulting in 1 
febrile convulsion, 0-10 years only 
400 Assumed, based on 57 
Number of vaccine doses resulting in 1 
anaphylaxis 
719790 Assumed, based on 56 
Cost of acute treatment   
Cost of ambulance transfer to hospital, call 
(£) 
7.73 58 
Cost of ambulance, see and treat and convey 
(£) 
229.61 58 
Cost per spell in hospital, (£) 2936.20 58 
Cost per High Dependency Unit day, 
paediatric (29 days to ≤18 years) (£) 
1038.27 58 
Cost per Intensive Therapy Unit day, 
paediatric 29 days to ≤18 years (£) 
1924.90 58 
Cost per critical care day, adult (19≥ 
years)(£) 
1188.94 58 
Cost of follow-up appointment, paediatric 
(≤18 years)(£) 
302.72 58 
Cost of follow-up appointment, adult (19≥ 
years)(£) 
279.98 58 
Cost of hearing assessment 58.93 58 
Public health response costs   
Cost of public health response to a case, 
excluding vaccine costs (£) 
80 22, Charlotte Chamberlain, 
personal communication 
Costs of long-term care   
Cost of support/care for those with mild 
sequelae (annual, £) 
1383.19 John Edmunds (London 
School of Hygiene and 
Tropical Medicine) 
 Parameter Base case Reference/source 
personal communication 
Cost of support/ care for those with severe 
sequelae (annual, £) 
4603.01 John Edmunds (London 
School of Hygiene and 
Tropical Medicine) 
personal communication 
Litigation costs   
Total costs per claim, child 1099424.00 Communication with 
Department of Health 
(Health Protection 
Analytical Team) 
Total costs per claim, adult 357165.00 Communication with 
Department of Health 
(Health Protection 
Analytical Team) 
Vaccination costs   
Cost per vaccine dose (£) 75.00 22 
Cost of administration - school (per dose, £) 10.00 Department of Health 
standard figures 
Cost of administration - GP surgery (per 
dose, £) 
7.50 Department of Health 
standard figures 
Meningococcal group C conjugate 
vaccination costs (annual cost) 
9575338.00 Based on Department of 
Health standard costs of 
administration and 22 
Costs for adverse reactions due to 
vaccination 
  
GP consultation cost, mild reactions (£) 31.00 59 
Adverse reaction (anaphylaxis), 
hospitalisation cost (£) 
463.00 58 
Adverse reaction (febrile convulsion), 
hospitalisation cost, <1 year (£) 
547.12 58 
Adverse reaction (febrile convulsion), 
hospitalisation cost, 1-18 years (£) 
520.30 58 
*Hospital Episode Statistics data from 2005/06-2011/12 were obtained from the University of 
Bristol. In scenario analyses HES data from 2010/11-2011/12 were used to provide a recent 
estimate of incidence and case fatality. 
†Due to the severity of disease all cases were assumed to be hospitalised. 
‡Proportion and length of stay in High Dependency Units and Intensive Therapy Units was 
based on data Hospital Episode Statistics data from 1997/98 to 2005/06, from a previous study 
(Christensen et al. Vaccine 2013; 31(23): 2638-46). The recording of critical care ceased within 
Hospital Episode Statistics ceased in March 2006. Critical care data are now collected under a 
new system, however the dataset is still experimental with known issues surrounding quality and 
coverage of certain key fields, thus the previous HES data has been used here. 
